IS8438A - Setin tríasól sem natríum gangahemla - Google Patents

Setin tríasól sem natríum gangahemla

Info

Publication number
IS8438A
IS8438A IS8438A IS8438A IS8438A IS 8438 A IS8438 A IS 8438A IS 8438 A IS8438 A IS 8438A IS 8438 A IS8438 A IS 8438A IS 8438 A IS8438 A IS 8438A
Authority
IS
Iceland
Prior art keywords
pain
alone
pharmaceutically acceptable
effective amount
compounds
Prior art date
Application number
IS8438A
Other languages
English (en)
Inventor
K. Park Min
K. Chakravarty Prasun
Zhou Bishan
Gonzalez Edward
Ok Hyun
Palucki Brenda
H. Parsons William
Sisco Rosemary
H. Fisher Michael
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of IS8438A publication Critical patent/IS8438A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
IS8438A 2003-11-10 2006-05-04 Setin tríasól sem natríum gangahemla IS8438A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51889003P 2003-11-10 2003-11-10
PCT/US2004/037280 WO2005047270A2 (en) 2003-11-10 2004-11-05 Substituted triazoles as sodium channel blockers

Publications (1)

Publication Number Publication Date
IS8438A true IS8438A (is) 2006-05-04

Family

ID=34590316

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8438A IS8438A (is) 2003-11-10 2006-05-04 Setin tríasól sem natríum gangahemla

Country Status (17)

Country Link
US (2) US20090074890A1 (is)
EP (1) EP1694654B1 (is)
JP (1) JP2007510741A (is)
KR (1) KR20060123739A (is)
CN (1) CN1922156A (is)
AT (1) ATE500234T1 (is)
AU (1) AU2004289694B2 (is)
BR (1) BRPI0416319A (is)
CA (1) CA2545254A1 (is)
DE (1) DE602004031667D1 (is)
IL (1) IL175522A0 (is)
IS (1) IS8438A (is)
NO (1) NO20062676L (is)
NZ (1) NZ547044A (is)
RU (1) RU2372339C2 (is)
WO (1) WO2005047270A2 (is)
ZA (1) ZA200603583B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
KR100808551B1 (ko) 2006-12-01 2008-03-03 한국생명공학연구원 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물
JP5523839B2 (ja) 2007-02-08 2014-06-18 シンタ ファーマシューティカルズ コーポレーション 癌などの増殖障害の治療に有用なトリアゾール化合物
BR122015028990B8 (pt) * 2007-04-03 2017-12-26 Du Pont composto, composições fungicidas e método de controle de doenças das plantas
CN101910412B (zh) * 2007-10-25 2013-08-21 利发利希奥公司 调节细胞膜介导的细胞内信号转导的组合物和方法
JP5586470B2 (ja) * 2007-10-25 2014-09-10 リバルシオ コーポレイション 静菌性または殺菌性組成物および方法
WO2009067600A2 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating inflammation
EP2222639A1 (en) 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
US20130296358A1 (en) 2012-05-03 2013-11-07 Ameet Vijay Ambarkhane 3-spirocyclic piperidine derivatives as ghrelin receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
AU2001245897B2 (en) * 2000-03-24 2006-07-06 Euro-Celtique S.A. Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
US20060183897A1 (en) * 2003-03-18 2006-08-17 Chakravarty Prasun K Biaryl substituted triazoles as sodium channel blockers
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers

Also Published As

Publication number Publication date
US7459475B2 (en) 2008-12-02
AU2004289694A1 (en) 2005-05-26
ATE500234T1 (de) 2011-03-15
EP1694654B1 (en) 2011-03-02
JP2007510741A (ja) 2007-04-26
DE602004031667D1 (de) 2011-04-14
CN1922156A (zh) 2007-02-28
BRPI0416319A (pt) 2007-01-09
RU2006120426A (ru) 2007-12-27
US20090074890A1 (en) 2009-03-19
CA2545254A1 (en) 2005-05-26
KR20060123739A (ko) 2006-12-04
WO2005047270A2 (en) 2005-05-26
ZA200603583B (en) 2007-08-29
NZ547044A (en) 2010-05-28
US20060020006A1 (en) 2006-01-26
RU2372339C2 (ru) 2009-11-10
EP1694654A2 (en) 2006-08-30
WO2005047270A3 (en) 2005-09-22
AU2004289694B2 (en) 2010-05-13
NO20062676L (no) 2006-08-10
IL175522A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
IS8438A (is) Setin tríasól sem natríum gangahemla
JO2480B1 (en) Triple aryl substituted with aryl as a sodium channel blocking agent
RU2329062C2 (ru) Способы и композиции для снятия боли
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
WO2007145922A3 (en) Benzazepinones as sodium channel blockers
ES2151599T3 (es) Acidos hidroxamicos substituidos con arilsulfonamido como inhibidores de matriz metaloproteinasas.
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
MXPA06002668A (es) Agonista de a-2 no sedante de 1-(2,3-dimetil-fenil)-etil-1, 3-dihidro-imidazol-2-tiona.
EA200300172A1 (ru) Метод обезболивания
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
PL1664016T3 (pl) Środki terapeutyczne przydatne do leczenia bólu
GEP20125389B (en) Substituted pyrazole and triazole compounds as ksp inhibitors
EA201071395A1 (ru) Ингибитор толерантности к анальгетику
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
WO2006009893A3 (en) Cancer chemotherapy
RS51211B (sr) Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja
MX2022011240A (es) Azálidos de urea inmunomoduladores.
MY160963A (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
MX2024002892A (es) Azalidos inmunomoduladores.
MX2023011554A (es) Composicion farmaceutica para la prevencion o tratamiento de enfermedad inflamatoria intestinal que actua como un antagonista funcional para s1pr1 y s1pr4.